Exchange transfusion for hemolytic hyperbilirubinemia: could some be averted by emergent administration of an inhibitor of bilirubin production?
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
04
05
2020
accepted:
07
07
2020
revised:
01
06
2020
pubmed:
17
7
2020
medline:
1
9
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
The objective of this study is to explore the hypothetical number of neonates where an exchange transfusion (ET) could be prevented by emergency administration of an inhibitor of bilirubin production. We identified all neonates who received an ET in our NICUs during the past 12 years. We reviewed the indications for ET and recorded the time between ordering and beginning the exchange. Forty-six neonates underwent ET, 37 (80.4%) for hemolytic hyperbilirubinemia (36.9 ± 2.9 weeks gestation and 2.5 ± 2.1 days old at ET). The mean delay period was 7.5 ± 3.5 h. Nine (19.6%) had ET not involving bilirubin. A trial testing compounds that can inhibit bilirubin production would have about three eligible neonates/years in our system. Since our births are 1% of national, up to 300 neonates/years might qualify for such a study.
Identifiants
pubmed: 32669646
doi: 10.1038/s41372-020-0736-8
pii: 10.1038/s41372-020-0736-8
doi:
Substances chimiques
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
860-864Références
Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics. 2007;120:27–32.
pubmed: 17606558
Maisels MJ. Neonatal hyperbilirubinemia and kernicterus—not gone but sometimes forgotten. Early Hum Dev. 2009;85:727–32.
pubmed: 19833460
Maisels MJ. Phototherapy—traditional and nontraditional. J Perinatol. 2001;21:S93–7.
pubmed: 11803426
Watchko JF. TcB, FFR, phototherapy and the persistent occurrence of kernicterus spectrum disorder. J Perinatol. 2020;40:177–9.
pubmed: 31911651
Dennery PA. Metalloporphyrins for the treatment of neonatal jaundice. Curr Opin Pediatr. 2005;17:167–9.
pubmed: 15800405
Stevenson DK, Wong RJ. Metalloporphyrins in the management of neonatal hyperbilirubinemia. Semin Fetal Neonatal Med. 2010;15:164–8.
pubmed: 20006567
Wong RJ, Vreman HJ, Schulz S, Kalish FS, Pierce NW, Stevenson DK. In vitro inhibition of heme oxygenase isoenzymes by metalloporphyrins. J Perinatol. 2011;31 Suppl 1:S35–41.
pubmed: 21448202
Maisels MJ, Yang H. Tin-mesoporphyrin in the treatment of refractory hyperbilirubinemia due to Rh incompatibility. J Perinatol. 2012;32:899–900.
pubmed: 23128060
Chavez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. JAMA. 1991;265:3270–4.
pubmed: 1904504
Bhutani VK, Poland R, Meloy LD, Hegyi T, Fanaroff AA, Maisels MJ. Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia. J Perinatol. 2016;36:533–9.
pubmed: 26938918
Diamond LK. Historic perspective on exchange transfusion. Vox Sang. 1983;45:333–5.
pubmed: 6356589
Fischer HS, Staufner C, Sallmon H, Henning S, Bührer C. Early exchange transfusion to treat neonates with gestational alloimmune liver disease—an 11-year cohort study. J Pediatr Gastroenterol Nutr. 2020;70:444–9.
pubmed: 31880662
Chinn IK, Eckstein OS, Peckham-Gregory EC, Goldberg BR, Forbes LR, Nicholas SK, et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018;132:89–100.
pubmed: 29632024
pmcid: 6034641
Kuperman A, Hoffmann Y, Glikman D, Dabbah H, Zonis Z. Severe pertussis and hyperleukocytosis: is it time to change for exchange? Transfusion. 2014;54:1630–3.
pubmed: 24330004
Romano MJ, Weber MD, Weisse ME, Siu BL. Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: improvement in oxygenation after a double volume exchange transfusion. Pediatrics. 2004;114:e264–6.
pubmed: 15286267
Hayasaka I, Cho K, Morioka K, Kaneshi Y, Akimoto T, Furuse Y, et al. Exchange transfusion in patients with Down syndrome and severe transient leukemia. Pediatr Int. 2015;57:620–5.
pubmed: 25615715
Runco DV, Josephson CD, Raikar SS, Goldsmith KC, Lew G, Pauly M, et al. Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction. Transfusion. 2018;58:1149–56.
pubmed: 29399859
pmcid: 5912979
Rets A, Clayton AL, Christensen RD, Agarwal AM. Molecular diagnostic update in hereditary hemolytic anemia and neonatal hyperbilirubinemia. Int J Lab Hematol. 2019;41 Suppl 1:95–101.
pubmed: 31069991
Christensen RD, Yaish HM, Wiedmeier SE, Reading NS, Pysher TJ, Palmer CA, et al. Neonatal death suspected to be from sepsis was found to be kernicterus with G6PD deficiency. Pediatrics. 2013;132:e1694–8.
pubmed: 24218468
Pearson CH. Replacement transfusion as a treatment of erythroblastosis fetalis, by Louis K. Diamond, MD. Pediatrics. 1998;102:203–5.
pubmed: 9651427
Diamond LK. The Rh problem through a retrospectroscope. Philip Levine Award presentation. Am J Clin Pathol. 1974;62:311–24.
pubmed: 4213493
Britten AF. Neonatal exchange transfusion: present status. Clin Pediatr. 1968;7:125–8.
Freda VL, Gorman JG, Pollack W, Robertson JG, Jennings ER, Sullivan JF. Successful prevention of experimental Rh sensitization in man with an anti-Rh gamma2-globulin antibody preparation: a preliminary report. Transfusion. 1964;4:26–32.
pubmed: 14105934
Freda VL, Gorman JG, Pollack W, Bowe E. Prevention of Rh hemolytic disease—ten years’ experience with Rh immunization. N Engl J Med. 1975;292:1014–6.
pubmed: 804134
Chavez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. JAMA. 1991;265:3270–4.
pubmed: 1904504
Sato K, Hara T, Kondo T, Iwao H, Honda S, Ueda K. High-dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility. Acta Paediatr Scand. 1991;80:163–6.
pubmed: 1709770
Merchant RH, Pradeep S. Intravenous immunoglobulin therapy for hyperbilirubinemia caused by rhesus hemolytic disease. Indian Pediatr. 1994;31:1269–71.
pubmed: 7875791
Alpay F, Sarici SU, Okutan V, Erdem G, Ozcan O, Gökçay E. High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr. 1999;88:216–9.
pubmed: 10102158
Walsh SA, Yao N, El-Khuffash A, Twomey A, Molloy EJ. Efficacy of intravenous immunoglobulin in the management of haemolytic disease of the newborn. Ir Med J. 2008;101:46–8.
pubmed: 18450249
Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM, et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics. 2011;127:680–6.
pubmed: 21422084
Santos MC, Sá C, Gomes SC Jr, Camacho LA, Moreira ME. The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double-blind trial. Transfusion. 2013;53:777–82.
pubmed: 22882285
van Klink JM, van Veen SJ, Smits-Wintjens VEHJ, Lindenburg ITM, Rijken M, Oepkes D, et al. Immunoglobulins in neonates with rhesus hemolytic disease of the fetus and newborn: long-term outcome in a randomized trial. Fetal Diagn Ther. 2016;39:209–13.
pubmed: 26159803
Louis D, More K, Oberoi S, Shah PS. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2014;99:F325–31.
pubmed: 24514437
Zwiers C, Scheffer-Rath ME, Lopriore E, de Haas M, Liley HG. Immunoglobulin for alloimmune hemolytic disease in neonates. Cochrane Database Syst Rev. 2018;3:CD003313.
pubmed: 29551014
Chessman JC, Bowen JR, Ford JB. Neonatal exchange transfusions in tertiary and non-tertiary hospital settings, New South Wales, 2001-2012. J Paediatr Child Health. 2017;53:447–50.
pubmed: 28370676
Murki S, Kumar P. Blood exchange for treatment of neonatal jaundice. Curr Opin Pediatr. 2005;15:167–9.
Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics. 1997;99:1–6.
Patra K, Storfer-Esser A, Siner B, Moore J, Hack M. Adverse events associated with neonatal exchange transfusions in the 1990’s. J Pediatr. 2004;144:626–31.
pubmed: 15126997
Kappas A, Drummond GS, Munson DP, Marshall JR. Sn-Mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah’s Witness newborns as an alternative to exchange transfusion. Pediatrics. 2001;108:1374–7.
pubmed: 11731664
Reddy P, Najundaswamy S, Mehta R, Petrova A, Hegyi T. Tin-mesoporphyrin in the treatment of severe hyperbilirubinemia in a very-low-birth-weight infant. J Perinatol. 2003;23:507–8.
pubmed: 13679941
Goldberg C, Levinson B, Mahoney M, Drummond GS, Bhutani VK. Use of stannsoporfin as an adjuvant to phototherapy to prevent need for exchange transfusion in near term and term infants. Pediatr Res. 2004;55:459(A).
Kappas A, Drummond GS, Manola T, Petmezaki S, Valaes T. Sn-protoporphyrin use in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility. Pediatrics. 1988;81:485–97.
pubmed: 3281127
Valaes T, Drummond GS, Kappas A. Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns using an inhibitor of bilirubin production, Sn-mesoporphyrin. Pediatrics. 1998;101:1–7.
Kappas A, Drummond GS, Henschke C, Valaes T. Direct comparison of Sn-mesoporhyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-term newborns. Pediatrics. 1995;95:468–74.
pubmed: 7700742
Valaes T, Petmezaki S, Henschke C, Drummond GS, Kappas A. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin. Pediatrics. 1994;93:1–11.
pubmed: 8265301
Martinez JC, Garcia HO, Otheguy LE, Drummond GS, Kappas A. Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin. J Perinatol. 1999;103:1–5.
Kappas A, Drummond GS, Valaes T. A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phoshate dehydrogenase-deficient newborns. Pediatrics. 2001;108:25–30.
pubmed: 11433050
Fujioka K, Kalish F, Wong RJ, Stevenson DK. Inhibition of heme oxygenase activity using a microparticle formulation of zinc protoporphyrin in an acute hemolytic newborn mouse model. Pediatr Res. 2016;79:251–7.
pubmed: 26488552